Moderna, Inc.
MRNA · Healthcare · Biotechnology
Updated 27 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #202 of 500 by Iconic Score · #23 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Moderna Inc. is a biotechnology company focused on drug discovery and development, particularly in the field of messenger RNA (mRNA) technology. With a market capitalization of $23.6 billion, Moderna gained prominence for its rapid development of a COVID-19 vaccine, which has positioned it as a leader in the mRNA therapeutics space. The company's innovative platform has potential applications beyond vaccines, including treatments for various infectious diseases, cancer, and rare genetic disorders. Moderna's strong pipeline and partnerships with government and private entities underscore its significant role in advancing healthcare solutions. As the biotechnology sector continues to evolve, Moderna's focus on mRNA technology could reshape therapeutic approaches and contribute to addressing unmet medical needs globally.
IconicOracleAI™ Brief
Moderna Inc's Iconic Score of 57 reflects a moderate brand presence amid a competitive healthcare landscape. Recent headlines highlight the company's efforts to diversify its respiratory portfolio, which may influence perceptions of its reliance on COVID-19 products. Additionally, the strong brand visibility signal of 85/100 suggests effective logo recognition, although the company faces challenges in standing out against competitors like Johnson & Johnson and Eli Lilly, as noted in broader market discussions.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.